Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund

INTRODUCTION: Heterozygous familial hypercholesterolemia (FH) is characterized by an elevated plasma low-density lipoprotein cholesterol (LDL-C) concentration despite intensive statin and ezetimibe therapy, which significantly increases the cardiovascular risk. AIM: The study evaluated the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobrowska, Beata, Krawczyk-Ożóg, Agata, Bartuś, Stanisław, Rajtar-Salwa, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421525/
https://www.ncbi.nlm.nih.gov/pubmed/36051838
http://dx.doi.org/10.5114/aic.2022.118533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421525/
https://www.ncbi.nlm.nih.gov/pubmed/36051838
http://dx.doi.org/10.5114/aic.2022.118533

Ejemplares similares